Drugs that contain Ubrogepant
1. List of Ubrelvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9499545 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8912210 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8754096 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US10117836 | ALLERGAN | Tablet formulation for CGRP active compounds |
Jan, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 23, 2024 |
NCE-1 date: December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with headache, with or without aura in adults
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic